BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 28522811)

  • 1. PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness.
    Chang K; Qu Y; Dai B; Zhao JY; Gan H; Shi G; Zhu Y; Shen Y; Zhu Y; Zhang H; Ye D
    Sci Rep; 2017 May; 7(1):2074. PubMed ID: 28522811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 expression and infiltration by CD4
    Lee HJ; Shin DH; Lee YJ; Lee SJ; Hwang CS; Kim A; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Park SW
    Histopathology; 2020 Apr; 76(5):714-721. PubMed ID: 31841221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 expression in nonclear-cell renal cell carcinoma.
    Choueiri TK; Fay AP; Gray KP; Callea M; Ho TH; Albiges L; Bellmunt J; Song J; Carvo I; Lampron M; Stanton ML; Hodi FS; McDermott DF; Atkins MB; Freeman GJ; Hirsch MS; Signoretti S
    Ann Oncol; 2014 Nov; 25(11):2178-2184. PubMed ID: 25193987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xp11.2 Translocation Renal Cell Carcinoma: Clinical Characteristics and Potential Prognostic Predictors.
    Dong J; Xu W; Ji Z; Pan B
    Dis Markers; 2021; 2021():5647933. PubMed ID: 34512814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphorylated 4EBP1 is associated with tumor progression and poor prognosis in Xp11.2 translocation renal cell carcinoma.
    Qu Y; Zhao R; Wang H; Chang K; Yang X; Zhou X; Dai B; Zhu Y; Shi G; Zhang H; Ye D
    Sci Rep; 2016 Mar; 6():23594. PubMed ID: 27026382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Xp11 translocation renal cell carcinoma morphologically mimicking clear cell-papillary renal cell carcinoma in an adult patient: report of a case expanding the morphologic spectrum of Xp11 translocation renal cell carcinomas.
    Parihar A; Tickoo SK; Kumar S; Arora VK
    Int J Surg Pathol; 2015 May; 23(3):234-7. PubMed ID: 25519951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
    Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
    Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Xp11.2 translocation renal neoplasm with features of TFE3 rearrangement associated renal cell carcinoma and Xp11 translocation renal mesenchymal tumor with melanocytic differentiation harboring NONO-TFE3 fusion gene.
    Yu W; Wang Y; Rao Q; Jiang Y; Zhang W; Li Y
    Pathol Res Pract; 2019 Sep; 215(9):152521. PubMed ID: 31277953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinomas.
    Mosquera JM; Dal Cin P; Mertz KD; Perner S; Davis IJ; Fisher DE; Rubin MA; Hirsch MS
    Diagn Mol Pathol; 2011 Sep; 20(3):129-37. PubMed ID: 21817901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Xp11 translocation renal cell carcinoma in adults: a clinicopathological and comparative genomic hybridization study.
    Zou H; Kang X; Pang LJ; Hu W; Zhao J; Qi Y; Hu J; Liu C; Li H; Liang W; Yuan X; Li F
    Int J Clin Exp Pathol; 2014; 7(1):236-45. PubMed ID: 24427344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.
    Malouf GG; Camparo P; Oudard S; Schleiermacher G; Theodore C; Rustine A; Dutcher J; Billemont B; Rixe O; Bompas E; Guillot A; Boccon-Gibod L; Couturier J; MoliniƩ V; Escudier B
    Ann Oncol; 2010 Sep; 21(9):1834-1838. PubMed ID: 20154303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The multislice CT findings of renal carcinoma associated with XP11.2 translocation/TFE gene fusion and collecting duct carcinoma.
    Zhu QQ; Wang ZQ; Zhu WR; Chen WX; Wu JT
    Acta Radiol; 2013 Apr; 54(3):355-62. PubMed ID: 23446748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic Characteristics and Prognosis of Xp11.2 Translocation Renal Cell Carcinoma: Multicenter, Propensity Score Matching Analysis.
    Choo MS; Jeong CW; Song C; Jeon HG; Seo SI; Hong SK; Byun SS; Chung JS; Hong SH; Hwang EC; Kim HH; Kwak C;
    Clin Genitourin Cancer; 2017 Oct; 15(5):e819-e825. PubMed ID: 28549862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues.
    Ning XH; Gong YQ; He SM; Li T; Wang JY; Peng SH; Chen JC; Liu JY; Qi NN; Guo YL; Gong K
    Oncotarget; 2017 Jan; 8(2):3355-3363. PubMed ID: 27926518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanotic Xp11 translocation renal cancer: report of a case with a unique intratumoral sarcoid-like reaction.
    Ritterhouse LL; Cykowski MD; Hassell LA; Slobodov G; Bane BL
    Diagn Pathol; 2014 Apr; 9():81. PubMed ID: 24735727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA expression profiling of Xp11 renal cell carcinoma.
    Marchionni L; Hayashi M; Guida E; Ooki A; Munari E; Jabboure FJ; Dinalankara W; Raza A; Netto GJ; Hoque MO; Argani P
    Hum Pathol; 2017 Sep; 67():18-29. PubMed ID: 28411178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers.
    Argani P; Hicks J; De Marzo AM; Albadine R; Illei PB; Ladanyi M; Reuter VE; Netto GJ
    Am J Surg Pathol; 2010 Sep; 34(9):1295-303. PubMed ID: 20679884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bilateral Xp11.2 translocation renal cell carcinoma: a case report.
    Karashima T; Kuno T; Kuroda N; Satake H; Fukata S; Chikazawa M; Kawada C; Yamasaki I; Shuin T; Hiroi M; Inoue K
    BMC Urol; 2018 Nov; 18(1):106. PubMed ID: 30458744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors Associated with Survival From Xp11.2 Translocation Renal Cell Carcinoma Diagnosis-A Systematic Review and Pooled Analysis.
    Wu Y; Chen S; Zhang M; Liu K; Jing J; Pan K; Zhang L; Xu B; Lu X; Chen M
    Pathol Oncol Res; 2021; 27():610360. PubMed ID: 34257577
    [No Abstract]   [Full Text] [Related]  

  • 20. Preoperative neutrophil-to-lymphocyte ratio predicts the surgical outcome of Xp11.2 translocation/TFE3 renal cell carcinoma patients.
    Agizamhan S; Qu F; Liu N; Sun J; Xu W; Zhang L; Guo H; Gan W
    BMC Urol; 2018 Jun; 18(1):60. PubMed ID: 29890986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.